Myriad Genetics Inc. will return for a repeat engagement of its Phase I collaboration with Biomarin Pharmaceuticals Inc. to deliver BRAC testing for Biomarin’s pivotal Phase III trials of BMN 673. BMN 673 is an oral poly ADP-ribose polymerase (PARP) inhibitor designed to kill BRCA-deficient cancer cells.